News
Analysts tip Inventiva's lanifibranor as NASH blockbuster
Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals i
